Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
CD137 Agonists Market: Competitive Landscape, Pipeline, and Market Analysis 2023
CD137 Agonists Market: Competitive Landscape, Pipeline, and Market Analysis 2023
CD137 (Cluster Differentiation 137) also known as immune checkpoint, is a type 1 transmembrane protein, expressed on the cell surface after T cell activation. CD137 acts as a co-stimulatory molecule functioning to stimulate T cell proliferation, dendritic cell maturation, and promotion of B cell antibody secretion. CD137 agonists exert their effect by stimulating cytotoxic T cell response against tumor cells resulting in tumor clearance, which is achieved by promoting the proliferation and survival of activated CD8+ T cells and upregulating their activity and effector functioning allowing for increased levels of cytokine production, which results in increased formation of memory T cells crucial for creating a long-term tumor response. CD137 agonists are currently in clinical trial phases for conditions such as solid tumors, colorectal cancer, non-hodgin’s lymphoma, malignant melanoma, anal cancer, cervical cancer, head and neck cancer, acute myeloid leukaemia, and others. BMS, Ono Pharma, Pfizer, Biokin Pharma, BeiGene, Crescendo Biologics, Roche are some of the major players in the CD137 agonists market.
Key Market Developments:
Approved Drug Molecules and Brand Names for CD137 Agonists:
Drugs under the Pipeline for CD137 Agonists:
Clinical Activity and Developments of CD137 Agonists:
Currently, there are more than 50 drug products in the CD137 Agonists, and all of them are in the clinical development phases.
|
Molecular Name |
Number of Studies |
|
Urelumab (BMS-663513) |
19 |
|
Utomilumab (PF-05082566) |
17 |
|
ADG106 |
8 |
|
Emfizatamab (GNC-038) |
6 |
|
LVGN6051 |
5 |
|
GEN1042 |
3 |
|
HLX35 |
3 |
|
INBRX-105 |
3 |
|
Acasunlimab (GEN1046) |
3 |
|
Cinrebafusp alfa (PRS-343) |
3 |
|
ABP-300 |
2 |
|
ATG-101 |
2 |
|
BGB-B167 |
2 |
|
CB307 |
2 |
|
DSP-107 |
2 |
|
EU101 |
2 |
|
PE0116 |
2 |
|
PRS-344 |
2 |
|
QLF31907 |
2 |
|
RG7827 |
2 |
|
YH004 |
2 |
|
Sytalizumab (TWP-101) |
2 |
|
ABL105 |
1 |
|
ABL503 |
1 |
|
ADG206 |
1 |
|
AGEN2373 |
1 |
|
AP203 |
1 |
|
ATOR-1017 |
1 |
|
BI 765179 |
1 |
|
BT7480 |
1 |
|
CTX-471 |
1 |
|
EU204 |
1 |
|
EU210 |
1 |
|
FS120 |
1 |
|
FS222 |
1 |
|
GNC-039 |
1 |
CD137 agonists are currently in preclinical trials for colorectal cancer, in phase-I for solid tumors, non-hodgkin’s lymphoma, malignant melanoma, anal cancer, cervical cancer, head and neck cancer, glioma, follicular lymphoma, ovarian cancer, leukaemia, and others, in phase-I/II for acute myeloid leukaemia, diffuse large B cell lymphoma, squamous cell cancer, HER2 negative breast cancer, non-small cell lung cancer, and others, in phase-II for breast cancer, oropharyngeal cancer, gastric cancer, and others.
According to the World Health Organization’s cancer report 2020, there were 1,92,92,789 new cases of cancer globally, in 2020. As per the International cancer data, cases of incidence will increase from 19 million in 2020 to 29 million in 2040. Breast cancer was the most common cancer occurring in women (22,61,419 patients globally), with the highest number of cancer cases in the USA (253,465 patients), followed by France (58,083), and Australia (19,617 patients) in 2020. In the case of oropharyngeal cancer, India had the highest number of new cases (20,617), followed by the USA (12,775), and China (5,607). For gastric cancer, approximately 1.1 million new cases were estimated in 2020, with the highest incidence rate in Eastern Asia, Japan, Mongolia, and Korea. All these increasing cases of cancer signal the growth potential for the CD137 agonists market.
Latin America
Europe
Asia Pacific
Middle East
North America
Download Free Sample Report
Urelumab (BMS-663513), Utomilumab (PF-05082566), Emfizatamab (GNC-038), Acasunlimab (GEN1046), Cinrebafusp alfa (PRS-343), and Sytalizumab (TWP-101) are some of the drugs in the pipeline for CD137 agonists.
BMS, Ono Pharma, Pfizer, Biokin Pharma, BeiGene, Crescendo Biologics, Roche are some of the major players in the CD137 agonists market.
Major indications for CD137 agonists are acute myeloid leukaemia, diffuse large B cell lymphoma, squamous cell cancer, HER2 negative breast cancer, non-small cell lung cancer, breast cancer, oropharyngeal cancer, and gastric cancer.
There are more than 50 molecules in the clinical development phases for CD137 agonists.
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.